Daisaku Yamada1, Hidetoshi Eguchi2, Tadafumi Asaoka1, Hideo Tomihara1, Takehiro Noda1, Hiroshi Wada1, Koichi Kawamoto1, Kunihito Gotoh1, Yutaka Takeda1,3, Masahiro Tanemura1,4, Masaki Mori1, Yuichiro Doki1. 1. Department of Gastroenterological Dr.surgery, Graduate School of Medicine, Osaka University, Yamadaoka 2-2 (E2), Suita, 565-0871, Osaka, Japan. 2. Department of Gastroenterological Dr.surgery, Graduate School of Medicine, Osaka University, Yamadaoka 2-2 (E2), Suita, 565-0871, Osaka, Japan. heguchi@gesurg.med.osaka-u.ac.jp. 3. Department of Surgery, Kansai Rosai Hospital, Inabasou 3-1-69, Amagasaki, Hyogo, 660-8511, Japan. 4. Department of Surgery, Osaka Police Hospital, Tennoji-ku Kitayamacho 10-31, Osaka, Osaka, 543-0035, Japan.
Abstract
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is highly lethal, and several clinical trials have shown that adjuvant chemotherapy after curative resection can improve the prognosis of these patients. However, the adjuvant chemotherapy completion rate is less than satisfactory. If this rate could be increased then the overall prognosis of PDAC might be improved; however, reports addressing this problem are insufficient. To elucidate the factors, we retrospectively investigated PDAC patients. METHODS: Various factors of 121 PDAC patients undergoing R0 resection, including preoperatively treated patients, were investigated. Univariate and multivariate analyses were performed to investigate the factors that were associated with the completion of adjuvant chemotherapy. RESULTS: The analysis identified age and the prognostic nutritional index (PNI) as significant independent factors. A receiver operating characteristic curve analysis of age yielded a cutoff value of 67 years (sensitivity, 64%; specificity, 78%). Univariate and multivariate analyses of the 61 patients who were over 67 years of age revealed that the PNI (odds ratio, 0.85; P = 0.048) and Evans grade (odds ratio, 0.041; P = 0.0010) were significant factors for the completion of chemotherapy. CONCLUSIONS: The results of our investigation suggest that nutrition should be controlled in older PDAC patients to facilitate the completion of adjuvant chemotherapy.
PURPOSE:Pancreatic ductal adenocarcinoma (PDAC) is highly lethal, and several clinical trials have shown that adjuvant chemotherapy after curative resection can improve the prognosis of these patients. However, the adjuvant chemotherapy completion rate is less than satisfactory. If this rate could be increased then the overall prognosis of PDAC might be improved; however, reports addressing this problem are insufficient. To elucidate the factors, we retrospectively investigated PDAC patients. METHODS: Various factors of 121 PDAC patients undergoing R0 resection, including preoperatively treated patients, were investigated. Univariate and multivariate analyses were performed to investigate the factors that were associated with the completion of adjuvant chemotherapy. RESULTS: The analysis identified age and the prognostic nutritional index (PNI) as significant independent factors. A receiver operating characteristic curve analysis of age yielded a cutoff value of 67 years (sensitivity, 64%; specificity, 78%). Univariate and multivariate analyses of the 61 patients who were over 67 years of age revealed that the PNI (odds ratio, 0.85; P = 0.048) and Evans grade (odds ratio, 0.041; P = 0.0010) were significant factors for the completion of chemotherapy. CONCLUSIONS: The results of our investigation suggest that nutrition should be controlled in older PDAC patients to facilitate the completion of adjuvant chemotherapy.
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: Alain Sauvanet; Jean-Marie Boher; François Paye; Philippe Bachellier; Antonio Sa Cuhna; Yves-Patrice Le Treut; Mustapha Adham; Jean-Yves Mabrut; Laurence Chiche; Jean-Robert Delpero Journal: J Am Coll Surg Date: 2015-04-14 Impact factor: 6.113
Authors: Douglas B Evans; Gauri R Varadhachary; Christopher H Crane; Charlotte C Sun; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Huamin Wang; Karen R Cleary; Gregg A Staerkel; Chusilp Charnsangavej; Elizabeth A Lano; Linus Ho; Renato Lenzi; James L Abbruzzese; Robert A Wolff Journal: J Clin Oncol Date: 2008-07-20 Impact factor: 44.544
Authors: Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler Journal: N Engl J Med Date: 2013-10-16 Impact factor: 91.245
Authors: Jin He; Barish H Edil; John L Cameron; Richard D Schulick; Ralph H Hruban; Joseph M Herman; Lei Zheng; Christine Iacobuzio-Donahue; Nita Ahuja; Timothy M Pawlik; Christopher L Wolfgang Journal: J Gastrointest Surg Date: 2012-11-27 Impact factor: 3.452
Authors: Mara H Sherman; Ruth T Yu; Dannielle D Engle; Ning Ding; Annette R Atkins; Herve Tiriac; Eric A Collisson; Frances Connor; Terry Van Dyke; Serguei Kozlov; Philip Martin; Tiffany W Tseng; David W Dawson; Timothy R Donahue; Atsushi Masamune; Tooru Shimosegawa; Minoti V Apte; Jeremy S Wilson; Beverly Ng; Sue Lynn Lau; Jenny E Gunton; Geoffrey M Wahl; Tony Hunter; Jeffrey A Drebin; Peter J O'Dwyer; Christopher Liddle; David A Tuveson; Michael Downes; Ronald M Evans Journal: Cell Date: 2014-09-25 Impact factor: 41.582
Authors: Max Heckler; Ulla Klaiber; Felix J Hüttner; Sebastian Haller; Thomas Hank; Henrik Nienhüser; Philip Knebel; Markus K Diener; Thilo Hackert; Markus W Büchler; Pascal Probst Journal: J Cachexia Sarcopenia Muscle Date: 2021-09-20 Impact factor: 12.910